Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy versus surgery alone for high-risk retroperitoneal sarcoma
2019-003543-30Phase 3Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of doxorubicin, epirubicin, dacarbazine and ifosfamide in retroperitoneal leiomyosarcoma (RLMS), retroperitoneal liposarcoma (RLS), dedifferentiated liposarcoma (DDL) and 1 more (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Disease-free survival. Status: unknown.
02
Drugs
doxorubicinepirubicindacarbazineifosfamide
03
Conditions
retroperitoneal leiomyosarcoma (RLMS)retroperitoneal liposarcoma (RLS)dedifferentiated liposarcoma (DDL)retroperitoneal sarcoma (RPS)
Beyond the preview
Go deeper on 2019-003543-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003543-30.